NCT00100854View on ClinicalTrials.gov

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

October 28, 2004

Primary Completion Date

September 5, 2018

Study Completion Date

September 5, 2018

Conditions

Lung Cancer

Interventions

DRUG

erlotinib hydrochloride

Given orally

DRUG

fulvestrant

Given intramuscularly

Trial Locations (1)

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Translational Oncology Research International

OTHER

NCT00100854 - Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter